Verrica Pharmaceuticals (NASDAQ:VRCA – Get Free Report) issued its quarterly earnings results on Thursday. The company reported ($0.58) EPS for the quarter, missing analysts’ consensus estimates of ($0.50) by ($0.08), Zacks reports. Verrica Pharmaceuticals had a negative return on equity of 407.11% and a negative net margin of 102.84%. The business had revenue of $6.91 million for the quarter, compared to analyst estimates of $6.20 million.
Here are the key takeaways from Verrica Pharmaceuticals’ conference call:
- U.S. YCANTH net product revenue reached a record $5.7 million, up 57.9% year over year, although dispensed units dipped slightly from Q2, which management attributed to seasonal patterns. The company also reported improved revenue yield per prescription as it works to reduce access and fulfillment issues.
- Verrica completed enrollment in the first pivotal common-warts trial, COVE-2, and exceeded 50% enrollment in COVE-3 ahead of schedule; top-line results are expected in Q1 and mid-2027, respectively. Management said Torii is funding the first $40 million—about 90% of the program’s current budget—and sees a potentially large market if YCANTH is approved for this use.
- Verrica is exploring an early proof-of-concept study of VP-315 in Gorlin syndrome, where patients face repeated BCCs and substantial surgical burden. The study design, costs, and timing are still being finalized, and management said its results could help guide the broader VP-315 development strategy.
- GAAP net loss widened to $12.4 million from $0.3 million a year earlier, while total revenue fell to $6.9 million from $14.3 million, largely because the prior-year quarter included a one-time $10 million Torii milestone. Verrica had $14.4 million in cash at quarter-end and said its runway could extend beyond the common-warts readouts into Q4 2027 if it draws the remaining $15 million available under its credit facility.
Verrica Pharmaceuticals Stock Performance
NASDAQ:VRCA opened at $3.72 on Friday. The company has a debt-to-equity ratio of 0.18, a quick ratio of 1.33 and a current ratio of 1.45. Verrica Pharmaceuticals has a fifty-two week low of $3.08 and a fifty-two week high of $9.82. The company has a 50 day simple moving average of $4.10 and a two-hundred day simple moving average of $5.43. The company has a market capitalization of $63.91 million, a PE ratio of -2.23 and a beta of 1.69.
Wall Street Analyst Weigh In
A number of research firms recently weighed in on VRCA. Lake Street Capital assumed coverage on Verrica Pharmaceuticals in a report on Thursday, August 27th. They issued a “buy” rating and a $9.00 price objective for the company. Wall Street Zen downgraded Verrica Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Saturday, November 7th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Verrica Pharmaceuticals in a research report on Tuesday, October 13th. Three investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $12.67.
Read Our Latest Report on Verrica Pharmaceuticals
Verrica Pharmaceuticals Company Profile
Verrica Pharmaceuticals Inc. is a dermatology-focused biopharmaceutical company developing and commercializing therapies for skin diseases that have limited or inadequate treatment options. The company’s activities center on prescription products designed for use by dermatologists and other healthcare professionals. Verrica’s lead commercial product is YCANTHE (cantharidin) topical solution, 0.7%, a prescription treatment approved by the U.S. Food and Drug Administration for molluscum contagiosum in adults and children two years of age and older.
Read More
- Five stocks we like better than Verrica Pharmaceuticals
- Costco’s Record $30 Dividend Shows Just How Strong Its Cash Machine Is
- Heavy Lifting: Can USA Rare Earth Turn Its First Sales Into Big Profits?
- These 3 Stocks Have Bought Back Billions, But Which Offers the Best Value?
- Golden Dome’s $185 Billion Question: Who Actually Gets Paid?
Receive News & Ratings for Verrica Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verrica Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
